Drugs / Magnesium
Magnesium
Trials 41
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT03879707 | Jun 2025 → Jun 2028 | — | Stanford University | Withdrawn | No outcome recorded |
| Phase 13 trials · 1 met primary | ||||||
| Phase 1 | NCT06209229 | May 2022 → May 2023 | non-small cell lung carcinoma | MIPO Clinic | Completed | No outcome recorded |
| Phase 1 | NCT04532775 | Aug → Dec 2020 | peripheral neuropathy | Fayoum University | Unknown | Met primary |
| Phase 1 | NCT00346658 | Jul 2002 → Sep 2006 | osteoporosis | University of Tennessee | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT02709031 | Jun 2022 → Jun 2024 | diabetes mellitus, hypertensive disorder, potassium deficiency | Navitas Pharma | Unknown | No outcome recorded |
| Phase 1/2 | NCT02602483 | Dec 2015 → Dec 2016 | temporomandibular joint disorder | Spherium Biomed | Completed | No outcome recorded |
| Phase 211 trials · 1 missed | ||||||
| Phase 2 | NCT07458022 | Dec 2025 → Apr 2026 overdue | major depressive disorder | University of Child Health Sciences and Children's Hospital, Lahore | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05837104 | Dec 2023 → Oct 2026 expected | bipolar I disorder, mixed anxiety and depressive disorder | Mclean Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT05806996 | Jul 2023 → Jun 2026 overdue | — | Mayo Clinic | Recruiting | No outcome recorded |
| Phase 2 | NCT03963479 | Jan → Jul 2019 | autism spectrum disorder | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | Unknown | No outcome recorded |
| Phase 2 | NCT03082625 | May 2017 → Mar 2018 | end stage renal failure | Sir Charles Gairdner Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT03063931 | Mar 2017 → Mar 2019 | — | University Hospital, Clermont-Ferrand | Unknown | No outcome recorded |
| Phase 2 | NCT01148888 | Jun 2010 → Jun 2012 | scoliosis | The Hospital for Sick Children | Completed | No outcome recorded |
| Phase 2 | NCT00808470 | Oct 2008 → Dec 2013 | noise induced hearing loss | University of Michigan | Completed | Missed primary |
| Phase 2 | NCT00242164 | Nov 2005 → Jun 2006 | cardiac rhythm disease, chronic kidney disease | University of Michigan | Completed | No outcome recorded |
| Phase 2 | NCT00276146 | May 2005 → ? | sickle cell disease | Children's Hospital Medical Center, Cincinnati | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00029510 | May 2002 → Jun 2006 | asthma | National Center for Complementary and Integrative Health (NCCIH) | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT02218424 | Oct 2014 → Apr 2015 | — | Ann & Robert H Lurie Children's Hospital of Chicago | Completed | No outcome recorded |
| Phase 35 trials | ||||||
| Phase 3 | NCT06904287 | Dec 2025 → Jun 2027 expected | migraine disorder | Wake Forest University Health Sciences | Recruiting | No outcome recorded |
| Phase 3 | NCT03033823 | Nov 2017 → Oct 2020 | alcohol withdrawal | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 3 | NCT00142233 | Jun 2005 → Sep 2019 | pancreatitis | University Medicine Greifswald | Completed | No outcome recorded |
| Phase 3 | NCT00250965 | Jul 2004 → Sep 2008 | coronary artery disorder, heart valve disorder | University of British Columbia | Terminated | No outcome recorded |
| Phase 3 | NCT00000610 | Apr 1998 → Nov 2003 | coronary artery disorder, myocardial infarction, myocardial ischemia | National Heart, Lung, and Blood Institute (NHLBI) | Completed | No outcome recorded |
| Phase 48 trials · 1 missed | ||||||
| Phase 4 | NCT07076069 | Jul 2025 → Jun 2028 expected | rotator cuff syndrome | Montefiore Medical Center | Recruiting | No outcome recorded |
| Phase 4 | NCT05947760 | Mar 2025 → Aug 2026 overdue | neuropathy, painful | University Hospitals Cleveland Medical Center | Active not recruiting | No outcome recorded |
| Phase 4 | NCT01756209 | Jan 2010 → Feb 2012 | migraine without aura | University of Catanzaro | Completed | No outcome recorded |
| Phase 4 | NCT02508857 | Jan 2010 → Jan 2014 | — | Cancer Institute of the State of São Paulo | Completed | No outcome recorded |
| Phase 4 | NCT00994981 | Sep 2007 → Sep 2008 | — | The Catholic University of Korea | Completed | No outcome recorded |
| Phase 4 | NCT01121653 | Mar 2006 → Jan 2008 | neuropathy, painful | University Hospital, Clermont-Ferrand | Completed | No outcome recorded |
| Phase 4 | NCT00325299 | ? → Sep 2005 | alcohol-induced disorders | Finnish Foundation for Alcohol Studies | Completed | Missed primary |
| Phase 4 | NCT02016495 | ? → Feb 2013 | pregnancy disorder | AGUNCO Obstetrics and Gynecology Centre | Completed | No outcome recorded |
| Phase not applicable10 trials | ||||||
| — | NCT07305519 | Apr 2026 → Apr 2027 expected | — | University of Roma La Sapienza | Recruiting | No outcome recorded |
| — | NCT07082894 | Jul 2025 → Apr 2026 | — | Tanta University | Completed | No outcome recorded |
| — | NCT07521358 | Jul → Aug 2025 | major depressive disorder | Hasanuddin University | Completed | No outcome recorded |
| — | NCT05851768 | May 2023 → Nov 2026 expected | — | National Cancer Institute, Egypt | Recruiting | No outcome recorded |
| — | NCT05485480 | Nov 2022 → Feb 2024 | — | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
| — | NCT04626063 | Jun 2018 → Mar 2019 | — | Istanbul University | Completed | No outcome recorded |
| — | NCT03355807 | Jan → Dec 2017 | opioid-induced constipation | Yeditepe University Hospital | Completed | No outcome recorded |
| — | NCT02982824 | Sep 2016 → Feb 2017 | epilepsy | Ain Shams University | Completed | No outcome recorded |
| — | NCT01679353 | Sep → Dec 2012 | — | Yonsei University | Completed | No outcome recorded |
| — | NCT01700998 | Sep 2012 → Oct 2014 | magnesium deficiency | Universidade do Extremo Sul Catarinense - Unidade Academica de Ciecias da Saude | Completed | No outcome recorded |
| Comparator or background therapy24 trials | ||||||
| Phase 1/2 | NCT06077539 Comparator | Sep 2023 → Apr 2024 | subacute delirium | Cairo University | Unknown | No outcome recorded |
| Phase 1/2 | NCT01146197 Background | Feb 2010 → Dec 2012 | Gitelman syndrome | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 2 | NCT06810765 Background | Sep 2025 → Dec 2026 | cognitive disorder, post-traumatic stress disorder, traumatic brain injury | Johns Hopkins University | Withdrawn | No outcome recorded |
| Phase 2 | NCT05586009 Comparator | Oct 2022 → Feb 2025 | cisplatin toxicity | Tanta University | Completed | No outcome recorded |
| Phase 2 | NCT03223519 Comparator | Jul → Nov 2017 | — | Spherium Biomed | Completed | No outcome recorded |
| Phase 2 | NCT00323583 Background | May 2006 → ? | pancreatic adenocarcinoma | Seattle Cancer Treatment and Wellness Center | Unknown | No outcome recorded |
| Phase 2 | NCT00041392 Comparator | Dec 2001 → May 2009 | coronary artery disorder | Duke University | Completed | No outcome recorded |
| Phase 2/3 | NCT06721247 Comparator | Nov 2024 → Nov 2025 overdue | asthma | Zagazig University | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT03367988 Background | Dec 2018 → Jan 2023 | drug dependence | University of South Florida | Unknown | No outcome recorded |
| Phase 3 | NCT07147972 Comparator | Aug 2025 → Feb 2026 overdue | migraine disorder | Fayoum University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT01087658 Background | Feb 2010 → Mar 2013 | colorectal neoplasm | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00641784 Comparator | Mar 2008 → Mar 2012 | — | MemorialCare | Terminated | No outcome recorded |
| Phase 4 | NCT06966102 Comparator | May → Jul 2025 overdue | — | Cairo University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT05488847 Background | Jun 2022 → Dec 2024 overdue | arthropathy | Henry Ford Health System | Active not recruiting | No outcome recorded |
| Phase 4 | NCT05149820 Comparator | Mar 2022 → Feb 2023 | atrial fibrillation, magnesium deficiency | University College, London | Unknown | No outcome recorded |
| Phase 4 | NCT00525317 Comparator | Jan 2002 → Sep 2004 | — | Oslo University Hospital | Completed | No outcome recorded |
| — | NCT04747171 Comparator | Apr → Jun 2021 | — | Benha University | Unknown | No outcome recorded |
| — | NCT04622904 Comparator | Nov 2020 → Nov 2023 | chronic pain syndrome, ketamine-induced biliary dilatation, magnesium deficiency | Aretaieion University Hospital | Unknown | No outcome recorded |
| — | NCT04603638 Comparator | Oct 2020 → Feb 2025 | — | Istanbul University | Completed | No outcome recorded |
| — | NCT04509401 Comparator | Jan → Nov 2020 | autism spectrum disorder 1 | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | Completed | No outcome recorded |
| — | NCT03132701 Comparator | Jun → Dec 2017 | delirium | Seoul National University Hospital | Completed | No outcome recorded |
| — | NCT02334059 Comparator | Nov 2015 → Mar 2019 | obesity disorder | Milton S. Hershey Medical Center | Completed | No outcome recorded |
| — | NCT02018276 Comparator | Dec 2013 → Oct 2014 | thyroid cancer | Yonsei University | Completed | No outcome recorded |
| — | NCT01727492 Comparator | Nov 2012 → ? | noise induced hearing loss, tinnitus | University Hospital, Antwerp | Unknown | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 66 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | magnesium | “This study proposes a randomized, double-blind, placebo-controlled crossover trial to assess the effects of a prophylactic combination of N-acetylcysteine (600 mg) and...” PMID 24708640 ↗ Apr 201464“Anesthesia will be maintained with Sevoflurane, Magnesium, Lidocaine, Ketamine, Decadron, Ondansetron, and Ketorolac at a concentration range/dose(s) based on the clinical need...” NCT03367988 ↗ “In addition to propofol as a hypnotic and rocuronium as a muscle relaxant, patients in the opioid-sparing group will receive Ketamine, Fentanyl, Lidocaine, Magnesium,...” NCT05485480 ↗ “Intraoperatively: Intravenous Dexamethasone 0.1mg/kg (maximum dose of 8mg), Magnesium 2g, Acetaminophen 1000mg, and local infiltration of 0.5% Ropivacaine 20ml” NCT07076069 ↗ “Magnesium supplementation administered orally at a dose of 350 mg once daily as adjunct therapy to fluoxetine for 6 weeks.” NCT07521358 ↗ “A bolus dose of magnesium of 50 mg/kg will be administered within 10 minutes preoperatively diluted in 100 mL of saline.” NCT04622904 ↗ “Magnesium (in the form of lactate dihydrate) 470 mg + pyridoxine (in the form of hydrochloride) 5 mg - take orally” NCT06209229 ↗ “Triple combination of Ibuprofen, Magnesium and Vitamin C Powder for oral solution administered TID for 3 days” NCT03223519 ↗ “Magnesium 50mg (Magnesium 10% 0.5mL)added to ropivacaine 0.15% 1.0ml/kg to Group MR.” NCT01679353 ↗ “a supplementation with potassium and magnesium will be orally given” NCT01146197 ↗ “Magnesium plus alpha-lipoic acid” NCT02016495 ↗ |
| Known as | Magnogene | “Magnogene ® (magnesium)” NCT01121653 ↗ |
| Known as | Magnésium UPSA Action Continue | “Magnesium: Magnésium UPSA Action Continue®” NCT03063931 ↗ |
| Action | Inhibit | “Magnesium is considered to be "nature's physiologic calcium blocker."” NCT00000610 ↗ |
| Modality | Other / unclassified | “As a physiological blocker of NMDAR, magnesium could be an interesting candidate to prevent postoperative pain and associated comorbidities, including cognitive and emotional...” PMID 30287600 ↗ Oct 2018 |
| Route | Intravenous | “intravenous bolus of magnesium sulphate administered over 15 minutes” NCT00000610 ↗ |